Thalassemia Treatment Trends and Forecast
The future of the global thalassemia treatment market looks promising with opportunities in the hospital and clinic and diagnostic laboratory markets. The global thalassemia treatment market is expected to reach an estimated $12.2 billion by 2030 with a CAGR of 5.1% from 2024 to 2030. The major drivers for this market are the increased prevalence of thalassemia, growing number of thalassemia medications under development, as well as, growing costs for pharmaceutical research and development as well as for healthcare.Thalassemia Treatment by Segment
The study includes a forecast for the global thalassemia treatment by type, treatment, end use, and region.Thalassemia Treatment Market by Type [Shipment Analysis by Value from 2018 to 2030]
- Alpha-Thalassemia
- Beta Thalassemia
Thalassemia Treatment Market by Treatment [Shipment Analysis by Value from 2018 to 2030]
- Blood Transfusions
- Iron Chelation Therapy
- Folic Acid Supplements
- Gene Therapy
- Bone Marrow Transplants
Thalassemia Treatment Market by End Use [Shipment Analysis by Value from 2018 to 2030]
- Hospital and Clinics
- Diagnostic Laboratories
- Others
Thalassemia Treatment Market by Region [Shipment Analysis by Value from 2018 to 2030]
- North America
- Europe
- Asia Pacific
- The Rest of the World
List of Thalassemia Treatment Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies thalassemia treatment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the thalassemia treatment companies profiled in this report include-- Novartis
- Bluebird Bio
- Kiadis Pharma
- CELGENE
- Sangamo Therapeutics
- Acceleron Pharma
- Gamida Cell
Thalassemia Treatment Market Insights
The publisher forecasts that blood transfusions is expected to witness the highest growth over the forecast period due to the low risk resulting from meticulous blood screening.North America will remain the largest region over the forecast period due to growing thalassemia awareness and government attempts to encourage gene treatment.
Features of the Global Thalassemia Treatment Market
- Market Size Estimates: Thalassemia treatment market size estimation in terms of value ($B).
- Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
- Segmentation Analysis: Thalassemia treatment market size by type, treatment, end use, and region in terms of value ($B).
- Regional Analysis: Thalassemia treatment market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
- Growth Opportunities: Analysis of growth opportunities in different type, treatment, end use, and regions for the thalassemia treatment market.
- Strategic Analysis: This includes M&A, new product development, and competitive landscape of the thalassemia treatment market.
- Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
FAQ
Q1. What is the thalassemia treatment market size?Answer: The global thalassemia treatment market is expected to reach an estimated $12.2 billion by 2030.
Q2. What is the growth forecast for thalassemia treatment market?
Answer: The global thalassemia treatment market is expected to grow with a CAGR of 5.1% from 2024 to 2030.
Q3. What are the major drivers influencing the growth of the thalassemia treatment market?
Answer: The major drivers for this market are the increased prevalence of thalassemia, growing number of thalassemia medications under development, as well as, growing costs for pharmaceutical research and development as well as for healthcare.
Q4. What are the major segments for thalassemia treatment market?
Answer: The future of the global thalassemia treatment market looks promising with opportunities in the hospital and clinic and diagnostic laboratory markets.
Q5. Who are the key thalassemia treatment market companies?
Answer: Some of the key thalassemia treatment companies are as follows:
- Novartis
- Bluebird Bio
- Kiadis Pharma
- CELGENE
- Sangamo Therapeutics
- Acceleron Pharma
- Gamida Cell
Answer: The publisher forecasts that blood transfusions is expected to witness the highest growth over the forecast period due to the low risk resulting from meticulous blood screening.
Q7. In thalassemia treatment market, which region is expected to be the largest in next 5 years?
Answer: North America will remain the largest region over the forecast period due to growing thalassemia awareness and government attempts to encourage gene treatment.
Q.8 Do we receive customization in this report?
Answer: Yes,the publisher provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the thalassemia treatment market by type (alpha-thalassemia and beta thalassemia), treatment (blood transfusions, iron chelation therapy, folic acid supplements, gene therapy, and bone marrow transplants), end use (hospital and clinics, diagnostic laboratories, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Global Thalassemia Treatment Market: Market Dynamics
3. Market Trends and Forecast Analysis from 2018 to 2030
4. Market Trends and Forecast Analysis by Region from 2018 to 2030
5. Competitor Analysis
6. Growth Opportunities and Strategic Analysis
7. Company Profiles of Leading Players
Companies Mentioned
- Novartis
- Bluebird Bio
- Kiadis Pharma
- CELGENE
- Sangamo Therapeutics
- Acceleron Pharma
- Gamida Cell
Methodology
The analyst has been in the business of market research and management consulting since 2000 and has published over 600 market intelligence reports in various markets/applications and served over 1,000 clients worldwide. Each study is a culmination of four months of full-time effort performed by the analyst team. The analysts used the following sources for the creation and completion of this valuable report:
- In-depth interviews of the major players in the market
- Detailed secondary research from competitors’ financial statements and published data
- Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
- A compilation of the experiences, judgments, and insights of professionals, who have analyzed and tracked the market over the years.
Extensive research and interviews are conducted in the supply chain of the market to estimate market share, market size, trends, drivers, challenges and forecasts.
Thus, the analyst compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. The analyst then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process.
LOADING...
